{"nctId":"NCT01186939","briefTitle":"An Extension to Study AZA PH GL 2003 CL 001 Allowing for Continuation of Azacitidine Treatment in Patients With Myelodysplastic Syndromes (MDS)","startDateStruct":{"date":"2007-04-01","type":"ACTUAL"},"conditions":["Myelodysplastic Syndromes"],"count":40,"armGroups":[{"label":"Azacitidine","type":"EXPERIMENTAL","interventionNames":["Drug: Azacitidine"]}],"interventions":[{"name":"Azacitidine","otherNames":["AZA"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Participants were considered eligible if they had been randomized to azacitidine treatment in the primary study and were receiving azacitidine at the time of study closure, had completed 12 months of treatment and observation in the primary study, and had signed the informed consent document for the extension phase of the study.\n* See study: AZA PH GL 2003 CL 001 for a list of inclusion criteria for the primary study.\n\nExclusion Criteria:\n\n* None specific to the extension phase of the study\n* See study: AZA PH GL 2003 CL 001 for a list of exclusion criteria for the primary study.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants in Different Categories of Treatment Emergent Adverse Events for the Extension Period","description":"Participant counts for a variety of subsets of treatment emergent adverse events (TEAEs)during the extension study period (43-68 months). Subsets include participants counts for serious TEAEs, serious TEAEs that the investigator evaluated as releated to treatment, TEAEs leading to discontinuation of therapy, or a dose reduction, or a dose interruption.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"39","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"27","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"20","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":20,"n":40},"commonTop":["Thrombocytopenia","Neutropenia","Anaemia","Diarrhoea","Injection site reaction"]}}}